Ophthalmic examination
Lens opacities, inflammation, Diabetic Retinopathy, mydriasis, Uveitis
INFLAMMATION, DIABETIC RETINOPATHY, UVEITIS
The examination included measurement of the best-corrected visual acuity (BCVA) expressed in letters using the Early Treatment Diabetic Retinopathy Study test, IOP measured by Perkins tonometry, and examination of the anterior pole with a slit-lamp and of the posterior pole under pharmacologic mydriasis. Lens opacities were recorded according to LOCS III classification [The clinical evaluation included one baseline visit, one PEI administration visit, and 6 months of follow-up visits over 12 months (see online supplementary table S2). The primary endpoint was safety, defined as the absence of ocular inflammation up to 12 months after treatment according to the Standardization of Uveitis Nomenclature for Reporting Clinical Data, i.e., reaction > 1+ in the anterior pole, the fibrinoid reaction in the anterior chamber, or reaction > 2+ in the vitreous [